Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 16Thoracic 6Lymphoid 6Genitourinary 6Gastrointestinal 6Tumor-Agnostic 2Sarcoma 2Gynecologic 2Endocrine 2Dermatologic 2Breast 2Plasma cell 1Other solid neoplasm 1Head & Neck 1

Conditions

Breast Neoplasms 2

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × antineoplaston AS 2-1 × Breast × Clear all
NCT00003454 2017-09-28

Antineoplaston Therapy in Treating Women With Stage IV Breast Cancer

Burzynski Research Institute

Phase 2 Terminated
19 enrolled
Breast

Breast Neoplasms

NCT00003455 2013-07-10

Antineoplaston Therapy in Treating Women With Advanced Breast Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡